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Abstract
the rapid antibiotic resistance development has creat-
ed a major demand for new antimicrobial agents that
can combat resistant strains such as methicillin-resis-
tant S. aureus (MRsa). Until a short time ago, the gly-
copeptide vancomycin was the only therapeutic choice
in this situation. However, in recent years some newer
agents  with  different  mechanisms  of  actions  have
been added to the arsenal, and more are on the hori-
zon. for a successful therapy it is of vital importance
that these compounds are used judiciously and dosed
appropriately. the present article reviews the pharma-
cokinetic properties of vancomycin, linezolid, tigecy-
cline and daptomycin. the first major difference be-
tween  these  compounds  is  their  oral  bioavailability.
only  linezolid  can  be  administered  orally,  whereas
vancomycin, daptomycin and tigecycline are limited to
parenteral use. once in the body, they show very dif-
ferent disposition. daptomycin has a very small vol-
ume of distribution of 7L indicating very little tissue
distribution whereas tigecycline has a very large vol-
ume of distribution of 350-500 L. Vancomycin and
linezolid are in-between with volumes of distribution
of approximately 30 and 50 L, close to total body wa-
ter. However, studies have shown that linezolid shows
better  tissue  penetration  than  vancomycin.  newer
studies  using  microdialysis,  a  new  technique  that  al-
lows direct monitoring of unbound tissue levels, sup-
port this finding. as far as drug elimination, dapto-
mycin and vancomycin are mainly eliminated into the
urine  and  require  dosing  adjustments  in  renally  im-
paired patients, whereas tigecycline is eliminated into
the bile and linezolid is metabolized so that in renal
patients no dosing adjustments are needed for these
compounds.  although  the  elimination  pathways  are
very different, the resulting half-lives of linezolid, van-
comycin, and daptomycin are not greatly different and
vary  from  4-8  h.  tigecycline,  however,  has  a  much
longer half-life of up to 1-2 days due to the slow redis-
tribution from tissue binding sites. 
IntRodUCtIon
appropriate treatment for serious infections caused by
drug resistant staphylococcus aureus represents a ma-
jor challenge for clinicians where failure can result in
patient  mortality.  although  newer  antibiotic  agents
have been developed, vancomycin continues to be the
most  commonly  preferred  drug  for  treating  serious
gram-positive infections involving methicillin-resistant
S. aureus (MRsa) and is often administered empirical-
ly to patients with serious infections due to methicillin
sensitive  S.  aureus (Mssa)  prior  to  microbiological
characterization. While numerous reports are available
that address vancomycin treatment outcomes in vari-
ous  populations  of  hospitalized  patients,  optimized
dosing strategies elude consensus at the same time that
treatment failure rates are high [1-3]. this report com-
pares pharmacokinetic properties of vancomycin and
selected  newer  agents  available  for  treating  patients
with serious MRsa infections. the respective pharma-
cokinetic properties are first presented for each com-
pound and then compared.
VanCoMyCIn
Vancomycin is indicated for susceptible strains of me-
thicillin-resistant  (beta-lactam-resistant)  staphylococci
[4].  It  is  indicated  for  penicillin-allergic  patients,  for
patients who cannot receive or who have failed to re-
spond  to  other  drugs,  including  the  penicillins  or
cephalosporins,  and  for  infections  caused  by  van-
comycin-susceptible  organisms  that  are  resistant  to
other antimicrobial drugs. Vancomycin is indicated for
initial  therapy  when  MRsa  are  suspected,  but  after
susceptibility data are available, therapy should be ad-
justed accordingly. 
Vancomycin is effective in the treatment of staphy-
lococcal endocarditis. Its effectiveness has been docu-
mented in other infections due to staphylococci, in-
cluding septicemia, bone infections, lower respiratory
tract  infections,  skin  and  skin  structure  infections.
When staphylococcal infections are localized and pu-
rulent, antibiotics are used as adjuncts to appropriate
surgical measures. 
Vancomycin has been reported to be effective alone
or in combination with an aminoglycoside for endo-
carditis caused by S.  viridans or S.  bovis. for endo-
carditis caused by enterococci (e.g., E. faecalis), van-
comycin  has  been  reported  to  be  effective  only  in
combination with an aminoglycoside. 
the ability of S. aureus to develop drug resistance
has been recognized for decades and the incidence of
serious MRsa infections continues to rise despite con-
siderable infection control efforts in hospital and com-
munity  settings  [5]  the  emergence  of  S.  aureus
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in the late 1990s triggered aggressive and costly mea-
sures to better control rates of infection and better
treat patients with serious drug resistant gram-positive
infections. surveillance investigations demonstrate an
increase in S. aureus isolates with reduced or “inter-
mittent”  sensitivity  to  vancomycin  (VIsa).  these
VIsa strains are identified as having in vitro minimum
inhibitory concentration (MIC) values to vancomycin
of 4 - 8 ʼg/mL [2, 6].
additionally, surveillance studies report a consistent
increase in mean MIC values for S. aureus isolates that
are  considered  susceptible  to  vancomycin.  this  in-
crease has been coined “MIC creep” [7]. the clinical
significance  of  increasing  MIC  within  the  sensitive
range was shown in a study comparing MIC and treat-
ment outcome in patients receiving vancomycin treat-
ment  for  MRsa  bacteremia  [8].  successful  bacteria
eradication  was  achieved  for  77  %  of  patients  with
MIC of 0.5 ﾵg/mL after a mean treatment time of 13
days, while the rate of eradication dropped to only 21
% after 18 days of vancomycin treatment in patients
with MRsa strains characterized as having a MIC of
2.0 ﾵg/mL. 
the  relatively  widespread  use  of  vancomycin  has
been  implicated  in  the  emergence  of  reduced  drug
sensitivity and its continued use as a first line treat-
ment for MRsa has been questioned in light of MIC
creep and high rates of treatment in failure for pa-
tients given doses that were considered adequate from
microbiological evaluation of bacterial isolates collect-
ed from sites of infection [7].
as  recently  reviewed,  vancomycin  is  among  the
most studied antibiotics with well described pharmaco-
kinetic  properties  [9].  Pharmacokinetic  studies  have
characterized vancomycin plasma concentrations with
one-,  two-,  and  three-compartment  pharmacokinetic
models. In patients with normal renal function, the dis-
tribution phase ranges from 0.5 to 1 hour, and the b-
elimination half-life usually ranges from 4 to 12 hours.
the volume of distribution is generally 0.4 – 1.0 L/kg
and protein binding is approximately 50 % [9].
the mechanism of action for vancomycin hinges
on the ability of the glycopeptide to complex with d-
ala moieties during peptidoglycan synthesis and block
formation of cell wall structural components. In vitro
studies demonstrate that vancomycin exhibits primari-
ly time dependent bactericidal activities and that high-
er  drug  concentrations  do  not  correlate  with  more
rapid killing. [10] several pharmacokinetic/pharmaco-
dynamic parameters were considered for vancomycin
dose monitoring and optimization including; time of
drug  plasma  concentration  above  the  MIC  within  a
dosing interval (t > MIC), the ratio of the area under
the  plasma  drug  concentration-versus-time  curve
(aUC) and the MIC (aUC/MIC), and the ratio of the
maximum  concentration  (Cmax)  over  MIC
(Cmax/MIC)  [9].  Early  studies  with  a  neutropenic
mouse thigh infection model indicated that aUC/MIC
for vancomycin correlated with drug efficacy, while a
clinical study in hospitalized patients with S.  aureus
lower respiratory tract infection found an aUC/MIC
ratio  ≥  400  was  associated  with  significantly  better
clinical  outcome  and  bacteriological  response  [11].
Compared  to  other  antibiotics,  an  efficacious
aUC/MIC ratio of 400 for vancomycin is relatively
high. However, protein binding and limited penetra-
tion to sites of infection must be considered.
Examination  of  study  results  in  ten  mechanically
ventilated  patients  with  bronchopneumonia  due  to
MRsa provides a more tangible rationale for targeting
serum  trough  concentrations  of  15-20  ﾵg/mL  for
treating  lung  infections.  the  study  compared  van-
comycin concentrations at the presumed site of infec-
tion, the epithelium lining fluid obtained during bron-
choalveolar  lavage,  with  plasma  trough  levels.  Van-
comycin was given intravenously at a daily dose of 30
mg/kg in four equal discontinuous infusions adminis-
tered for a 1 h period every 6 h which is similar to the
standard dosing of 2 g over 24 h. the resulting mean
trough  plasma  drug  concentration  was  16  ﾵg/mL.
Urea was used as an endogenous marker in this study
to quantify the volume of epithelium lining fluid. this
approach  resulted  in  highly  variable  values  for
amounts of epithelium lining fluid and has also been
criticized as overestimating epithelium lining fluid [12].
Interestingly, only 4 of 10 epithelium lining fluid sam-
ples contained detectable antibiotic with an average es-
timated concentration close to the MIC breakpoint of
2 ﾵg/mL. Each of the 4 cases with measurable drug in
epithelium  lining  fluid  was  from  a  subject  with  a
trough vancomycin serum concentration exceeding 20
ﾵg/mL. In contrast, patients with plasma trough gly-
copeptides concentrations ranging from approximately
8 to 18 ﾵg/mL had undetectable epithelium lining flu-
id levels [13].
the factors contributing to vancomycin distribution
to target sites of infection in alveolar tissue was ad-
dressed by scheetz who investigated the relationship
between  vancomycin  pulmonary  distribution  and
treatment outcomes in patients with MRsa pneumo-
nia [12]. no known active transport mechanisms for
vancomycin across membranes and passive transport
is responsible for penetration into tissues that are well
perfused such as lungs. Passive diffusion is a function
of protein binding, antibiotic molecular weight, lipid
solubility,  capillary  density,  capillary  and  membrane
permeability,  tissue  inflammation,  membrane  surface
area, and oncotic and osmotic gradients. Capillary per-
meability and oncotic gradients vary with inflamma-
tion, and may have an effect on pulmonary disposition
of  vancomycin.  the  authors  suggested  that  limited
drug access of the bulky hydrophilic moiety may ex-
plain why some data suggest concentration dependent
action  although  the  mechanism  of  action  for  van-
comycin should be time dependent. If only 20 % to 30
% of vancomycin serum concentration is achieved in
lung  tissue,  higher  target  concentrations  may  be  re-
quired to treat pneumonia.
Routine therapeutic drug monitoring reports only
total  vancomycin  concentrations,  although  protein
binding  varies  and  it  is  generally  accepted  that  only
free drug is active. a recent study evaluated total and
free drug in a group of 15 patients who were treated
by continuous infusion. the study found a wide varia-
tion  in  free  to  total  vancomycin  ratios  that  with  a
range of 12 - 100 % and mean of 63.6 ﾱ 25.8 %. the
correlation  between  free  and  total  vancomycin  was
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were large and no correlation could be made with pa-
tients' clinical conditions. the investigators concluded
that total vancomycin is not predictive of free van-
comycin  and  recommended  routine  monitoring  of
free drug concentrations [14].
In a retrospective study, Jeffres and co-investigators
examined  the  clinical  significance  of  trough  van-
comycin concentrations that met target levels in pa-
tients with health care associated pneumonia due to
MRsa isolates [15]. the investigators identified 102
incidents of MRsa with health care associated pneu-
monia  over  a  6.5-year  period  including  32  patients
(31.4  %)  who  died  during  their  hospitalization.  the
mean vancomycin trough concentrations did not differ
between survivors and treatment failures. the stratifi-
cation of the vancomycin trough concentrations and
aUC values yielded no relationship with hospital mor-
tality. the investigators concluded that aggressive dos-
ing strategies for vancomycin (eg, trough concentra-
tions of > 15 ﾵg/mL) may not offer any advantage
over traditional dose targets of 5 to 15 ﾵg/mL. target
doses have shifted upwards during the last decade as
reflected in a survey in Uk where trough values > 10
ﾵg/mL were considered toxic by vast majority of clini-
cians who used therapeutic drug monitoring [16].
Results of the Jeffres study also highlight the com-
plexity  of  translating  Pk/Pd  principles  for  van-
comycin [15]. the dosing strategy was similar with all
patients initially treated with vancomycin in daily doses
of 30 mg/kg in two divided doses duringa24-h period.
Vancomycin trough values were identified from serum
concentrations collected less than 30 min before ad-
ministering the fourth dose (at the onset of steady-
state conditions). In addition to the trough values, Jef-
fres et al estimated total drug exposure (aUC0-24) for
each patient from the ratio of administered dose ver-
sus  drug  clearance  (estimated  from  creatinine  clear-
ance). Considerable variation was identified among the
102 patients given weight based drug doses. the au-
thors noted that even the relationship between mea-
sured trough levels and estimated aUC0-24 was not ad-
equate to predict vancomycin exposure from weight
based intravenous administration at steady state [15]. 
Vancomycin  was  initially  associated  with  clinically
significant nephrotoxicity and ototoxicity. subsequent
manufacturing  methods  eliminated  components  that
were  thought  to  be  responsible  for  high  rates  of
nephrotoxicity observed with the initial product. sev-
eral studies examined the relationship between the pu-
rified vancomycin product and nephrotoxicity and re-
ported an incidence of 5-7 % that was considered in-
frequent and reversible. However the observed rates
of  nephrotoxicity  were  highly  variable  with  rates  as
high as 35 % in patients with vancomycin trough val-
ues exceeding 10 ﾵg/mL. the high rates were largely
attributed  to  baseline  differences  in  disease  severity
and  concomitant  nephrotoxin  use  across  trough
groups. several opinion papers questioned the need to
monitor vancomycin levels, because of the perception
that there was no relationship between exposure and
nephrotoxicity. the consensus asHP report on thera-
peutic  monitoring  of  vancomycin  in  adult  patients
published  in  2009  provided  an  extensive  review  of
available evidence for nephrotoxicity and ototoxicity
and  recommended  trough  concentration  monitoring
during  aggressive  vancomycin  treatment  targeted  to
achieve concentrations of 15-20 ﾵg/mL [9]. two stud-
ies  concluding  that  a  strong  relationship  exists  be-
tween the incidence of nephrotoxicity and high van-
comycin exposure are described below. 
an  increased  incidence  of  nephrotoxicity  in  pa-
tients with high (15 - 20 ﾵg/mL) compared to lower
(< 15 ﾵg/mL) trough vancomycin concentrations was
reported in a retrospective study that included 95 hos-
pitalized patients with MRsa infections [17]. authors
reported  nephrotoxcity  only  occurred  in  the  high
trough group with an incidence of 12 % (11 of 63 pa-
tients).  However,  10  of  the  11  patients  in  the  high
trough group with nephrotoxicity received concurrent
treatment with an aminoglycoside or amphotericin B.
a more recent study identified a strong relationship
between the initial trough vancomycin value and the
probability of nephrotoxicity in 166 patients [18]. the
authors found that higher trough concentrations, espe-
cially > 20 ﾵg/mL, were associated with an unaccept-
able risk of nephrotoxicity. the investigators further
noted that because the exposure targets for efficacy
are  rather  high  for  vancomycin  (with  an  aUC0–24ss
/MIC = 350 – 400), it will be difficult to achieve the
exposure endpoint associated with success for serious
methicillin-resistant  S.  aureus infections  with  MICs
close to 2 ﾵg/mL without subjecting the patient to a
relatively high risk of nephrotoxicity.
a major limitation of many published tissue distrib-
ution studies is the fact that they measure biopsies or
total tissue concentrations which cannot differentiate
between free and bound drug [19, 20]. this limitation
can be overcome with the method of microdialysis to
directly measure the active, unbound concentrations at
the tissue site [21, 22]. Vancomycin tissue concentra-
tions were measured in six diabetic and six nondiabetic
patients  after  cardiac  surgery  [23].  Vancomycin  was
administered as a continuous intravenous infusion at
an infusion rate of 80 to 120 mg/h. Vancomycin con-
centrations in soft tissues and plasma were measured
by microdialysis on day 8 ﾱ 4 after initiation of van-
comycin treatment. Vancomycin tissue concentrations
in  diabetic  patients  were  significantly  lower  than  in
nondiabetics.  the  median  vancomycintissue/vanco  -
mycinplasma concentration ratio was 0.1 in diabetic pa-
tients and 0.3 in nondiabetics (P = 0.002). the study
demonstrated that vancomycin penetration into target
tissues  is  substantially  impaired  in  diabetic  patients
versus nondiabetics. Insufficient tissue concentrations
could therefore possibly contribute to failure of an-
tibiotic treatment and the development of antimicro-
bial resistance in diabetic patients. 
LInEzoLId
Linezolid  is  the  first  approved  oxazolidinone  to  be
marketed and represents an antibiotic mechanism of
action  that  is  characteristic  of  this  class  of  com-
pounds. the drug inhibits the initiation of the synthe-
sis of bacterial proteins and enzymes, by preventing
the formation of the ternary complex at 70s riboso-
mal subunit by an apparent double blockade of both
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Linezolid is indicated in the treatment of gram-nega-
tive  infections  [25]:  vancomycin-resistant  E.  faecium
infections, including cases with concurrent bacteremia;
nosocomial  pneumonia  caused  by  S.  aureus (methi-
cillin-susceptible and -resistant strains), or S. pneumo-
niae (including multi-drug resistant strains); complicat-
ed skin and skin structure infections, including diabet-
ic foot infections, without concomitant osteomyelitis,
caused by S. aureus (methicillin-susceptible and -resis-
tant strains), S. pyogenes, or S. agalactiae; uncomplicat-
ed skin and skin structure infections caused by S. au-
reus (methicillin-susceptible only) or S. pyogenes; com-
munity-acquired pneumonia caused by S. pneumoniae
(including multidrug resistant strains), including cases
with concurrent bacteremia, or S. aureus (methicillin-
susceptible strains only).
Early studies demonstrated linear pharmacokinetics
with a dose proportional increase in aUC after intra-
venous doses up to the usual therapeutic dose of 600
mg. Importantly, linezolid demonstrated excellent and
complete oral bioavailability that allows ready conver-
sion from intravenous to oral dosing regimens. Line-
zolid protein-binding is approximately 30 % and the
drug is considered to show adequate penetration into
tissues at concentrations that are bactericidal [24].
Pharmacokinetic parameters for 600 mg oral doses
of linezolid after multiple dosing show Cmax values of
approximately 21 ﾵg/mL one hour after administra-
tion  and  a  half-life  of  5.4  hours  [24].  Results  from
pharmacokinetic  studies  conducted  with  linezolid  in
special populations were recently reviewed [26]. the
kidneys function as the primary route of excretion for
linezolid  with  both  unchanged  parent  drug  and
metabolites measured in urine accounting for most of
the dose. However, dose adjustments based on renal
function are not indicated based on clinical studies in
renally  impaired  patients.  Linezolid  aUC  increased
only 15 % in patients with markedly impaired renal
function  (creatinine  clearance  10-40  mL/min)  com-
pared  to  subjects  with  normal  renal  function  [27].
Linezolid  metabolite  levels  may  increase  in  patients
with severe renal impairment [24].
although  the  volumes  of  distribution  of  van-
comycin and linezolid do not differ by much, it could
be shown that linezolid provides a better tissue distrib-
ution  and  particularly  lung  penetration  than  van-
comycin [28]. In an analysis of a number of previous
studies,  linezolid  demonstrated  adequate  penetration
into lung and other soft issues with sustained concen-
trations above the minimum inhibitory concentrations
for  susceptible  pathogens,  including  MRsa,  for  the
majority of the dosing interval. In a study in healthy
volunteers, the ability of linezolid to penetrate soft tis-
sues in healthy volunteers was investigated [29]. ten
healthy volunteers were subjected to linezolid drug in-
take at a dose of 600 mg twice a day for 3 to 5 days.
the first dose was administered intravenously. all fol-
lowing doses were self-administered orally. the tissue
penetration of linezolid was assessed by use of in vivo
microdialysis. the study showed that linezolid pene-
trates rapidly into the interstitial space fluid of subcu-
taneous adipose and skeletal muscle tissues in healthy
volunteers. on the basis of pharmacokinetic-pharma-
codynamic calculations, it could be shown that linezol-
id concentrations in soft tissues can be considered suf-
ficient to inhibit the growth of many clinically relevant
bacteria. the microdialysis technology was then also
applied to studies in patients. In a study of inflamed
soft  tissue  and  bone  of  diabetic  patients  suffering
from severe bacterial foot infections, linezolid was ad-
ministered intravenously twice daily at a dosage of 600
mg [30]. at steady-state conditions, the microdialysis
was utilized to sample serially interstitial space fluid
from inflamed subcutaneous adipose tissue and bone.
the degree of tissue penetration was found to be ade-
quate in diabetic patients suffering from bacterial foot
infection complicated by osteomyelitis. 
septic shock and severe sepsis alters fluid dynamics
and  distribution  of  body  water  which  could  impact
drug  distribution  and  dosing.  Microdialysis  was  also
employed to show that sepsis did not have an impact
on tissue distribution [31]. sixteen patients with septic
shock and eight patients with severe sepsis were com-
pared with matched healthy controls. the results indi-
cated that the severity of sepsis had no substantial ef-
fect  on  the  pharmacokinetic  profile  of  linezolid  in
plasma and in the interstitium of soft tissues. In a sim-
ilar study in patients with sepsis or septic shock, also
microdialysis was utilized to monitor the tissue con-
centrations of linezolid [32].
Linezolid has limited hepatic metabolism however
the pharmacodynamics of the drug include inhibition
of monoamine oxidase activity and it is a substrate for
the drug transporter aBCB1 which suggest drug inter-
actions could be a clinical concern. Case reports pro-
vide limited evidence that caution should be used in
co-administering linezolid with drugs that alter sero-
tonergic function (citalopram, duloxetine, meperidine)
[26].  similarly,  the  synergism  between  rifampin  and
linezolid suggested from microbiological studies was
not supported by clinical results. the lower than ex-
pected  Csf  linezolid  concentrations  identified  when
rifampin was given in combination treatment was at-
tributed  to  aBCB1  transporter  induction  associated
with rifampin [26].
Linezolid is considered a time-dependent antibacte-
rial agent especially against S. aureus. Clinical experi-
ence identified targets for t > MIC of at least 80 % of
the dosing interval as well as a ratio of aUC/MIC ≥
100. these target parameters are consistent with the
relatively modest protein binding of linezolid and dis-
tribution parameters of the drug [33]. 
since its introduction linezolid has maintained ex-
cellent activity [34, 35]. However, some reports have
identified increased emergence of drug resistance [36-
39]. additionally, some dose limiting toxicity has been
found with standard twice daily 600 mg dosing regi-
mens that may limit use of the drug. It was also noted
that linezolid could affect its own metabolism as a re-
sult of protein synthesis inhibition in mitochondria,
and this could lead to high plasma concentrations and
increased risk of non-negligible toxicities [26]. 
tIgECyCLInE
tigecycline is a broad-spectrum bacteriostatic, or de-
pending on the microorganism, sometimes bacterioci-
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binding to the 30s subunit of the prokaryotic ribo-
some.  tigecycline  is  the  first  fda-approved  (2005)
representative of a new drug class, the glycylcyclines.
tigecycline shows activity against tetracycline-resistant
gram-positive,  gram-negative,  anaerobe  and  atypical
pathogens [40-45]. It is indicated for the treatment of
adults with (1) complicated skin and skin structure in-
fections;  (2)  complicated  intra-abdominal  infections;
and  (3)  community-acquired  bacterial  pneumonia
caused  by  S.  pneumoniae (penicillin-susceptible  iso-
lates), including cases with concurrent bacteremia, H.
influenzae  (beta-lactamase  negative  isolates),  and  L.
pneumophila [46].
In combination with its broad antimicrobial spec-
trum, a large volume of distribution (≥ 7 - 10 L/kg)
[47-49] and intracellular accumulation [49, 50] are fre-
quently  mentioned  as  providing  a  rationale  for  the
clinical use of tigecycline. Whether high tigecycline tis-
sue concentrations can be directly correlated to its an-
timicrobial activity has not yet been determined.
the pharmacokinetic and pharmacodynamic prop-
erties of tigecycline have recently be reviewed in detail
[51]. 
It  could  be  shown  that  tigecycline  features  linear
pharmacokinetics after single doses of 12.5 to 300 mg
and at steady state after doses between 25 to 100 mg
q12h [48]. this is supported by the fact that dose pro-
portionality is observed for maximum plasma concen-
trations  (Cmax)  and  areas  under  the  concentration-
time  curves  (aUC).  Closer  examination  of  the  data
from this pharmacokinetic study revealed that there is
an increase in the calculated distribution volume (2.8
to 12 L/kg) and half-life (11 to 46 h) values with single
increasing doses (12.5 - 300 mg) [48]. this dose-relat-
ed  behavior  indicates  non-linear  pharmacokinetics
which may be explained by concentration-dependent
plasma protein and/or tissue binding.
tigecycline exhibits non-linear plasma protein bind-
ing over therapeutic drug concentrations [47-49, 52,
53]. In contrast to the majority of drugs that show
non-linear binding, the unbound fraction decreases as
the  tigecycline  concentrations  increase  (29  %  at  0.1
ﾵg/mL vs. 11 % at 1.0 ﾵg/mL) [48]. It has been sug-
gested that this very unusual and atypical binding be-
havior is linked to the ability of tigecycline to form
chelate  complexes  with  multivalent  metal  ions  that
bind to plasma proteins. It has also been shown from
in vitro experiments that the formation of such tetra-
cycline chelate complexes can result in changes in dif-
fusion rates across membranes or alter binding to plas-
ma proteins [48, 54, 55]. However, it is currently not
clear whether this atypical binding behavior has any
impact on the pharmacokinetics of tigecycline. 
the mean clearance of tigecycline has been report-
ed to range between 0.19 and 0.34 L/h/kg [48, 56, 57].
although there appears to be some variability, there
seems to be no trend with ascending dose. a radiola-
bel study revealed that the major route of elimination
is  excretion  of  unchanged  tigecycline  in  the  feces,
which accounts for 59 % of the dose [58]. further-
more, results of this study show that, amongst others,
glucuronides and n-acetyl-9-aminominocycline are the
main metabolites of tigecycline [58]. Renal elimination
of unchanged drug is a minor pathway and accounts
for approximately 10 - 15 % of the dose [48].
tigecycline has a very large volume of distribution
of approximately 7-10 L/kg [47-49]. this extremely
large  volume  indicates  that  tigecycline  is  extensively
bound  in  the  tissues.  It  was  shown  that  tigecycline
could be found in virtually every body fluid, such as
bile,  epithelial  lining  fluid,  synovia  or  cerebrospinal
fluid and tissue, such as colon, lung and bone [59].
the  results  of  the  tissue  biopsy  studies  further  re-
vealed that the total concentrations in colon and lung
were higher than the corresponding tigecycline plasma
levels [59]. this data should be interpreted with great
caution, as it was obtained from tissue homogenates
and represents a mixture of both free and bound con-
centrations  from  different  compartments  within  the
tissues  (e.g.  interstitial  fluid,  cells,  capillaries).  these
measurements are of limited utility. a better approach
is again the use of microdialysis that directly measures
the unbound concentrations in the tissues. In a recent
study, tigecycline was measured by microdialysis in the
interstitial fluid of wound margins versus that of un-
infected thigh tissue in adult diabetic patients [53]. the
mean values for the unbound concentrations in plas-
ma, thigh, and wound free area under the concentra-
tion-time curve from 0 to 24 h were basically identical.
as previously observed in vitro, protein binding was
nonlinear, with the percentage of free drug increasing
with decreasing serum concentrations, a highly unusu-
al behavior. the data confirmed that one should be
very  cautious  in  interpreting  total  tissue  concentra-
tions and relating them to anti-infective activity.
the half-life of tigecycline is variable, reported val-
ues range from 15 to 67 h [48, 49, 60, 61]. since half-
life  is  a  secondary  pharmacokinetic  parameter,  vari-
ability in this parameter can be attributed to variability
in  the  primary  parameters,  clearance  and  volume  of
distribution. Results from pharmacokinetic studies dis-
play relatively consistent clearance values and indicate
volume of distribution as the main source for variabil-
ity, possible due to non-linearity in plasma and/or tis-
sue binding.
It  is  known  that  differences  in  pharmacokinetics
can  arise  between  gender  and  age  [62].  In  order  to
evaluate these effects on tigecycline’s pharmacokinet-
ics, a study was conducted in 46 healthy volunteers (21
females and 25 males) [57]. In this study, volunteers
received a single dose of 100 mg tigecycline that was
infused  over  60  min.  Volume  of  distributions  were
found to be approximately 350L for women and 500L
for men. However, weight-normalized volumes of dis-
tribution  were  not  significantly  different.  this  study
demonstrated that there is no difference in the phar-
macokinetics, based on age or sex and no dose adjust-
ments are needed.
the effect of renal function on the Pk of tigecy-
cline was investigated in a single dose study (100 mg
over 60 min). this study was performed in 6 healthy
volunteers,  6  patients  with  severe  renal  dysfunction,
and 8 patients with end-stage renal disease (EsRd) re-
quiring  hemodialysis  [63,  64].  Results  indicate  that
there was a decrease in the clearance in patients with
EsRd.  However,  while  the  aUCs  and  Cmax  values
were slightly higher in renally impaired patients, it was
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the  fact  that  these  changes  in  pharmacokinetics  did
not affect the tolerability of tigecycline. these find-
ings are not surprising as renal elimination is a sec-
ondary pathway along with metabolism to biliary/fecal
elimination [58].
since biliary excretion is one of the main elimina-
tion pathways of tigecycline, the effect of hepatic im-
pairment was investigated in 48 subjects (10 patients
with mild, 10 patients with moderate and 5 patients
with severe hepatic impairment as well as 23 age and
weight-matched  healthy  volunteers)  [47].  the  results
of this study show that there were similar plasma pro-
files  for  patients  with  mild  hepatic  impairment  and
healthy  individuals.  In  comparison,  in  patients  with
moderate  hepatic  impairment,  the  tigecycline  clear-
ance was 25 % lower and in patients with severe he-
patic  impairment,  clearance  was  reduced  by  55  %.
Based on these findings, it is recommended that pa-
tients with severe hepatic impairment should receive a
reduced maintenance dose of 25 mg BId, whereas the
loading dose does not need to be adjusted.
tigecycline shows little potential for drug interac-
tions  [47,  61].  no  dosage  adjustments  are  needed
when co-administered with warfarin [65].
tigecycline has almost no oral bioavailability [66]. It
is, therefore, administered as a short-term (30 - 60 min)
intravenous infusion [47]. a combination of a relative-
ly long half-life and pronounced post-antibiotic effect
of tigecycline would generally support an once daily
dosing regimen [67, 68]. However, due to gastrointesti-
nal adverse events, which seem to correlate with peak
plasma levels, peak concentrations are kept lower by
administering tigecycline as an initial 100 mg loading
dose, followed by a 50 mg maintenance dose every 12
hours  [48].  for  patients  with  severe  hepatic  impair-
ment, a reduced maintenance dose of 25 mg BId after
an initial 100 mg loading dose is recommended.
daPtoMyCIn
daptomycin is the only member of a class of antibi-
otics called lipopeptides. It has a mechanism of action
by which it interacts with the bacterial cell membrane
without entering the cell [69]. this interaction results
in very rapid killing of the bacteria. the mechanism of
action requires the presence of physiological concen-
trations of calcium ions. daptomycin is bacteriocidal
and active against gram-positive bacteria.
daptomycin  is  indicated  for  (1)  complicated  skin
and skin structure infections (csssI) caused by suscep-
tible  isolates  of  the  gram-positive  microorganisms.
Combination therapy may be clinically indicated if the
documented  or  presumed  pathogens  include  gram-
negative  or  anaerobic  organisms;  and  (2)  S.  aureus
bloodstream  infections  (bacteremia),  including  those
with right-sided infective endocarditis, caused by me-
thicillin-susceptible  and  methicillin-resistant  isolates.
Combination therapy may be clinically indicated if the
documented  or  presumed  pathogens  include  gram-
negative or anaerobic organisms [70]. 
daptomycin shows poor oral bioavailability and can
only  be  administered  parenterally  [71-76].  dosing  is
based on the body weight of the patient. the currently
recommended dose for skin and soft tissue infections
is 4 mg/kg once daily and for right-sided endocarditis
6  mg/kg  once  daily.  the  once-daily  dosing  regimen
could be shown to be better tolerated than previously
investigated twice daily treatments. Myopathy was an
adverse effect noted with twice daily dosing. dapto-
mycin has a very small volume of distribution of ap-
proximately 0.1 L/kg, one of the smallest volumes re-
ported for any drug. this small volume indicates that
there is very little tissue distribution and the majority
of the drug remains in the blood stream and extracel-
lular fluid space. the reason for the low volume of dis-
tribution is the drug’s high plasma protein binding that
has been reported to be 92 % [76]. this high plasma
protein binding always needs to be considered when
comparing  daptomycin  plasma  concentrations  with
their respective MIC values. as mentioned earlier, mi-
crodialysis is an appropriate technique to monitor the
unbound, active drug concentrations in tissues. for lo-
calized tissue infections, drug concentrations in the in-
terstitial space are an important determinant of suc-
cessful therapy. In the diabetic population, peripheral
arterial disease may limit antibiotic penetration into the
target  tissue.  In  a  recent  study,  the  pharmacokinetic
profiles of daptomycin in the interstitial fluid of soft
tissues were compared in diabetic and healthy volun-
teers by using in  vivo microdialysis [77]. twelve sub-
jects (six diabetic and six healthy) received a single 4
mg/kg dose of daptomycin intravenously. the degree
of tissue penetration, defined as the ratio of the area
under the free drug concentration-time curve for tissue
to that for plasma, was similar. daptomycin at 4 mg/kg
penetrated well into the soft tissue, reaching concentra-
tions approximately 70 to 90 % of those of the free
drug in plasma. Moreover, these free, bioactive concen-
trations in tissue exceeded the MICs for staphylococci
and streptococci over the 24-h dosing interval. 
However, the small volume of distribution of dap-
tomycin shows that the majority of the drug resides in
the plasma due its high plasma protein binding and
that the respective tissue binding is much less. dapto-
mycin is not an appropriate choice for intracellular in-
fections.
Caused primarily by gram-positive pathogens such
as S. aureus and, to a lesser extent, E. faecalis, bone
and joint infections are difficult to treat successfully.
In a recent analysis, the outcome of treating bone and
joint infections with daptomycin was evaluated [78].
Early clinical investigation of daptomycin in bone and
joint  infections  unresponsive  to  antibiotics,  such  as
vancomycin, showed a cure rate of approximately 80
%, with a low incidence of adverse events and drug
resistance.  the  authors  concluded  that  daptomycin
may be a promising option for patients with bone and
joint infections such as MRsa osteomyelitis.
the  half  life  of  daptomycin  is  approximately  8
hours [75, 76, 79, 80]. the reason for this long half-life
is the restricted glomerular filtration due to the high
protein binding. on the other hand, this long half-life
facilitates the possibility of a once-daily dosing regi-
men. approximately 60 % of the dose is eliminated
unchanged in the urine. as expected, patients with im-
paired  renal  function  show  longer  half-lives  and  re-
quire longer dosing intervals. Patients with end-stage
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40 ml/min or below require a dosage adjustment of 4
mg/kg once every 48 h. 
CoMPaRIson of tHE PHaRMaCokInEtIC
PRoPERtIEs
the four compounds that are compared in this report
are used for the treatment of MRsa and otherwise
difficult  to  control  infections.  It  is  important  to 
realize that their pharmacokinetic properties vary vast-
ly and that they cannot be simply used interchange-
ably. table 1 compares the most relevant pharmacoki-
netic properties of these compounds.
the  first  major  difference  between  these  com-
pounds is their oral bioavailability. only linezolid can
be  administered  orally,  whereas  vancomycin,  dapto-
mycin  and  tigecycline  are  limited  to  parenteral  use.
once in the body, they show very different disposi-
tion. daptomycin has a very small volume of distribu-
tion  of  7  L  indicating  very  little  tissue  distribution
whereas  tigecycline  has  a  volume  of  distribution  of
350-500 L. Vancomycin and linezolid are in-between
with volumes of distribution of approximately 30 and
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Table 1. approved indications and pharmacokinetic properties of vancomycin, linezolid, tigecycline and daptomycin [4, 25, 46, 70].
Vancomycin Linezolid Tigecycline Daptomycin
approved  serious or severe  Vancomycin- Complicated skin  Complicated skin 
Indications (fda) infections caused by  Resistant E. faecium and skin structure  and skin structure 
susceptible strains of  infections infections. infections.
methicillin-resistant 
(beta-lactam-resistant)  nosocomial Complicated intra- S. aureus
staphylococci. pneumonia caused  abdominal bloodstream
by S. aureus or  infections. infections
alone or in  S. pneumoniae (bacteremia), 
combination with an  including multi-drug  Community- including those with 
aminoglycoside for  resistant strains  acquired bacterial  right-sided infective 
endocarditis caused  pneumonia endocarditis, caused 
by S. viridans or  Complicated skin  by methicillin-
S. bovis. and skin structure  susceptible and 
infections, including  methicillin-resistant 
for endocarditis  diabetic foot  isolates. 
caused by  infections
enterococci (e.g., 
E. faecalis) only in  Uncomplicated skin 
combination with an  and skin structure 
aminoglycoside. infections caused by 
Mssa or 
S. pyogenes.
Community-
acquired pneumonia 
caused by Mssa
oral Bioavailability not absorbed not absorbed not absorbed Completely absorbed
Clearance 0.06 L/h/kg 0.01 L/h/kg 0.33 L/h/kg 0.10 L/h/kg
Volume of distribution 0.3 to 0.43 L/kg 0.1 L/kg 8-9 L/kg 0.7-0.8 L/kg
Half-Life 4-6 h 8 h 27-42 h 4-5 h
Protein Binding 55 % 90-93 % 71-89 % 31 %
Major Route of  renal renal biliary metabolism
Elimination 30 % renal
tissue Penetration moderate low very high high
Usual dosing  1000 mg IV 4-6 mg/kg IV  50 mg IV 600 mg IV 
Regimen over 60 min.  over 30 min.  over 30-60 min. over 30-120 min.
Q12h Q24h Q 12h Q12h
with drug Level  first dose 100 400-600 mg Po
Monitoring mg IV Q12h
dosing in Renal  Increased dosing  Increased dosing  no dose  no dose 
Impairment Interval with  Interval adjustment adjustment
drug Level 
Monitoring
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tion, daptomycin and vancomycin are mainly eliminat-
ed into the urine, whereas tigecycline is eliminated into
the bile and linezolid is metabolized. although these
pathways are very different, the resulting half-lives of
linezolid, vancomycin, and daptomycin are not greatly
different and vary from 4-8 h. tigecycline, however,
has a much longer half-life of up to 1-2 days due to
the slow redistribution from tissue binding sites. the
four drugs also differ in their affinity to bind to pro-
teins:  daptomycin  has  the  highest  protein  binding
with over 90 %, whereas vancomycin (55 %) and par-
ticularly  linezolid  (31  %)  show  much  lower  binding.
tigecycline binding is also high (70 - 90 %) featuring a
highly unusual inversed nonlinearity with higher un-
bound fractions at lower concentrations. the degree
of protein binding is clinically relevant since only the
unbound  drug  is  related  to  anti-infective  activity.  In
terms  of  the  pharmacodynamic  properties  the  four
candidate  drugs  also  differ  greatly:  daptomycin  is  a
rapid killer with bactericidal activity whereas the other
three provide much slower kill rates. daptomycin and
tigecycline  are  both  concentration-dependent  antibi-
otics indicating that high peak concentration will lead
to  increased  anti-infective  activity.  furthermore,  for
both drugs it has been shown that also the total daily
dose (as measured by the area under the curve) corre-
lates with therapeutic outcome. However, both drugs
show very different safety profiles. High peak concen-
trations of tigecycline are not well tolerated so that in
spite of its long half-life the total daily dose for tigecy-
cline is administered BId. In case of daptomycin it
could  be  shown  that  extending  the  dosing  interval
from twice daily to once-daily minimized the incidence
of myopathy so that daptomycin is administered once-
daily. Both linezolid and vancomycin are administered
BId in order to maintain sufficiently high trough con-
centrations.  Vancomycin  trough  concentrations  also
correlate with its nephrotoxicity so that they can be
monitored to minimize safety issues. for twice daily
dosing, a trough target range of 15-20 ﾵg/mL for mi-
croorganisms with a MIC > 1 ﾵg/mL is recommended
to  exceed  the  desired  aUC/MIC  ratio  of  400  and
minimize  toxicity.  no  drug  level  monitoring  is  re-
quired for any of the other three compounds.
so, in summary, one needs to take into account the
respective  pharmacokinetic  and  pharmacodynamic
properties when using each of the four compounds dis-
cussed in order to maximize the chance for a successful
therapeutic use. one can only hope that there will be
more efficacious antimicrobial choices available in the
not too far future since new resistance developments
will certainly challenge our current antibiotic arsenal.
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